Dr. rer. biol. hum. Sandra Rutzner

Lehrstuhl für Strahlentherapie Department of Radiation Oncology

Progress Patterns under Radioimmunotherapy - clinical Evaluation of the prospective STICI Study (2021) Schubert P, Schweizer C, Roesch J, Haderlein M, Rutzner S, Semrau S, Donaubauer AJ, et al. Conference contribution Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+T-cell infiltration. (2021) Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, et al. Conference contribution Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer (2021) Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, et al. Journal article The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Journal article, Review article Differences in and Prognostic Value of Quality of Life Data in Rectal Cancer Patients with and without Distant Metastases (2021) Frank F, Hecht M, Loy F, Rutzner S, Fietkau R, Distel L Journal article Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Conference contribution Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy (2020) Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, et al. Journal article Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors (2020) Schubert P, Rutzner S, Eckstein M, Frey B, Schweizer C, Haderlein M, Lettmaier S, et al. Journal article Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 (2020) Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, et al. Journal article